Markers for gastric cancer premalignant lesions: Where do we go?

Digestive Diseases

Volumn 30, Issue 3, 2012, Pages 268-276

  Leja, Marcis ^a   Wex, Thomas ^b   Malfertheiner, Peter ^b  

^a UNIVERSITY OF LATVIA   (Latvia)

^b OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

Biomarkers; Gastric cancer; Host genetics; Pepsinogen; Premalignant lesions

Indexed keywords

BIOLOGICAL MARKER; MICRORNA;

ATROPHY; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; CANCER STAGING; HEREDITY; HUMAN; METAPLASIA; PRIORITY JOURNAL; REVIEW; STOMACH CANCER;

ATROPHY; EARLY DETECTION OF CANCER; HUMANS; MICRORNAS; PRECANCEROUS CONDITIONS; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84862887379     PISSN: 02572753     EISSN: 14219875     Source Type: Journal    
DOI: 10.1159/000336990     Document Type: Review

References (80)

1. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Danesh J: Helicobacter pylori infection and gastric cancer: Systematic review of the epidemiological studies. Aliment Pharmacol Ther 1999; 13: 851-856. (Pubitemid 29312768)
3. Carpelan-Holmstrom M, Louhimo J, Stenman UH, Alfthan H, Haglund C: CEA, CA 19-9 and CA 72-4 improve the diagnostic accuracy in gastrointestinal cancers. Anticancer Res 2002; 22: 2311-2316. (Pubitemid 34857058)
4. Bornschein J, Kandulski A, Selgrad M, Malfertheiner P: From gastric inflammation to gastric cancer. Dig Dis 2010; 28: 609-614.
5. Correa P: A human model of gastric carcinogenesis. Cancer Res 1988; 48: 3554-3560.
6. Meining A, Morgner A, Miehlke S, Bayerdorffer E, Stolte M: Atrophy-metaplasia-dysplasia- carcinoma sequence in the stomach: A reality or merely an hypothesis? Best Pract Res Clin Gastroenterol 2001; 15: 983-998. (Pubitemid 34110604)
7. You WC, Brown LM, Zhang L, Li JY, Jin ML, Chang YS, Ma JL, Pan KF, Liu WD, Hu Y, Crystal-Mansour S, Pee D, Blot WJ, Fraumeni JF Jr, Xu GW, Gail MH: Randomized double- blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions. J Natl Cancer Inst 2006; 98: 974-983. (Pubitemid 44288162)
8. Srivastava A, Lauwers GY: Gastric epithelial dysplasia: the Western perspective. Dig Liver Dis 2008; 40: 641-649.
9. Dixon MF: Prospects for intervention in gastric carcinogenesis: Reversibility of gastric atrophy and intestinal metaplasia. Gut 2001; 49: 2-4. (Pubitemid 32601868)
10. Fichman S, Niv Y: Histological changes in the gastric mucosa after Helicobacter pylori eradication. Eur J Gastroenterol Hepatol 2004; 16: 1183-1188. (Pubitemid 39488792)
11. Wang J, Xu L, Shi R, Huang X, Li SW, Huang Z, Zhang G: Gastric atrophy and intestinal metaplasia before and after Helicobacter pylori eradication: A meta-Analysis. Digestion 2011; 83: 253-260.
12. Vannella L, Lahner E, Bordi C, Pilozzi E, Di Giulio E, Corleto VD, Osborn J, Delle Fave G, Annibale B: Reversal of atrophic body gastritis after H. pylori eradication at longterm follow-up. Dig Liver Dis 2011; 43: 295-299.
13. Watari J, Das KK, Amenta PS, Tanabe H, Tanaka A, Geng X, Lin JJ, Kohgo Y, Das KM: Effect of eradication of Helicobacter pylori on the histology and cellular phenotype of gastric intestinal metaplasia. Clin Gastroenterol Hepatol 2008; 6: 409-417.
14. Filipe MI, Munoz N, Matko I, Kato I, Pompe- Kirn V, Jutersek A, Teuchmann S, Benz M, Prijon T: Intestinal metaplasia types and the risk of gastric cancer: A cohort study in Slovenia. Int J Cancer 1994; 57: 324-329. (Pubitemid 24168604)
15. Cassaro M, Rugge M, Gutierrez O, Leandro G, Graham DY, Genta RM: Topographic patterns of intestinal metaplasia and gastric cancer. Am J Gastroenterol 2000; 95: 1431-1438. (Pubitemid 30396299)
16. El-Zimaity HM, Ramchatesingh J, Saeed MA, Graham DY: Gastric intestinal metaplasia: Subtypes and natural history. J Clin Pathol 2001; 54: 679-683. (Pubitemid 32835414)
17. de Vries AC, van Grieken NC, Looman CW, Casparie MK, de Vries E, Meijer GA, Kuipers EJ: Gastric cancer risk in patients with premalignant gastric lesions: A nationwide cohort study in the Netherlands. Gastroenterology 2008; 134: 945-952. (Pubitemid 351451990)
18. Gutierrez-Gonzalez L, Graham TA, Rodriguez- Justo M, Leedham SJ, Novelli MR, Gay LJ, Ventayol-Garcia T, Green A, Mitchell I, Stoker DL, Preston SL, Bamba S, Yamada E, Kishi Y, Harrison R, Jankowski JA, Wright NA, McDonald SA: The clonal origins of dysplasia from intestinal metaplasia in the human stomach. Gastroenterology 2011; 140: 1251-1260.e1-6.
19. El-Zimaity HM, Ota H, Graham DY, Akamatsu T, Katsuyama T: Patterns of gastric atrophy in intestinal type gastric carcinoma. Cancer 2002; 94: 1428-1436. (Pubitemid 34212636)
20. Nozaki K, Ogawa M, Williams JA, Lafleur BJ, Ng V, Drapkin RI, Mills JC, Konieczny SF, Nomura S, Goldenring JR: A molecular signature of gastric metaplasia arising in response to acute parietal cell loss. Gastroenterology 2008; 134: 511-522. (Pubitemid 351173056)
21. Goldenring JR, Nam KT, Wang TC, Mills JC, Wright NA: Spasmolytic polypeptide-expressing metaplasia and intestinal metaplasia: time for reevaluation of metaplasias and the origins of gastric cancer. Gastroenterology 2010; 138: 2207-2210, 10 e1.
22. Dinis-Ribeiro M, Yamaki G, Miki K, Costa- Pereira A, Matsukawa M, Kurihara M: Metaanalysis on the validity of pepsinogen test for gastric carcinoma, dysplasia or chronic atrophic gastritis screening. J Med Screen 2004; 11: 141-147. (Pubitemid 39274096)
23. di Mario F, Cavallaro LG: Non-invasive tests in gastric diseases. Dig Liver Dis 2008; 40: 523-530.
24. Watabe H, Mitsushima T, Yamaji Y, Okamoto M, Wada R, Kokubo T, Doi H, Yoshida H, Kawabe T, Omata M: Predicting the development of gastric cancer from combining Helicobacter pylori antibodies and serum pepsinogen status: A prospective endoscopic cohort study. Gut 2005; 54: 764-768. (Pubitemid 40732089)
25. Oishi Y, Kiyohara Y, Kubo M, Tanaka K, Tanizaki Y, Ninomiya T, Doi Y, Shikata K, Yonemoto K, Shirota T, Matsumoto T, Iida M: The serum pepsinogen test as a predictor of gastric cancer: the Hisayama study. Am J Epidemiol 2006; 163: 629-637.
26. Yanaoka K, Oka M, Yoshimura N, Mukoubayashi C, Enomoto S, Iguchi M, Magari H, Utsunomiya H, Tamai H, Arii K, Yamamichi N, Fujishiro M, Takeshita T, Mohara O, Ichinose M: Risk of gastric cancer in asymptomatic, middle-Aged Japanese subjects based on serum pepsinogen and Helicobacter pylori antibody levels. Int J Cancer 2008; 123: 917-926. (Pubitemid 352032422)
27. Yamaji Y, Watabe H, Yoshida H, Kawabe T, Wada R, Mitsushima T, Omata M: High-risk population for gastric cancer development based on serum pepsinogen status and lifestyle factors. Helicobacter 2009; 14: 81-86.
28. Miki K: Gastric cancer screening by combined assay for serum anti- Helicobacter pylori IgG antibody and serum pepsinogen levels - 'ABC method'. Proc Jpn Acad Ser B Phys Biol Sci 2011; 87: 405-414.
29. Miki K, Fujishiro M: Cautious comparison between East and West is necessary in terms of the serum pepsinogen test. Dig Endosc 2009; 21: 134-135.
30. Lomba-Viana R, Dinis-Ribeiro M, Fonseca F, Vieira AS, Bento MJ, Lomba-Viana H: Serum pepsinogen test for early detection of gastric cancer in a European Country. Eur J Gastroenterol Hepatol 2012; 24: 37-41.
31. Ito M, Yoshihara M, Takata S, Wada Y, Matsuo T, Boda T, Tanaka S, Chayama K: Serum screening for detection of the high-risk group for early-stage diffuse type gastric cancer in Japanese. J Gastroenterol Hepatol 2012;27:598-602.
32. Veres G, Pehlivanoglu E: Helicobacter pylori infection in pediatrics. Helicobacter 2007; 12(suppl 1):38-44. (Pubitemid 47312376)
33. Tseng FC, Brown EE, Maiese EM, Yeager M, Welch R, Gold BD, Owens M, Cranston B, Hanchard B, El-Omar E, Hisada M: Polymorphisms in cytokine genes and risk of Helicobacter pylori infection among Jamaican children. Helicobacter 2006; 11: 425-430. (Pubitemid 44352612)
34. Hishida A, Matsuo K, Goto Y, Hamajima N: Genetic predisposition to Helicobacter pylori -induced gastric precancerous conditions. World J Gastrointest Oncol 2010; 2: 369-379.
35. El-Omar EM, Carrington M, Chow WH, McColl KE, Bream JH, Young HA, Herrera J, Lissowska J, Yuan CC, Rothman N, Lanyon G, Martin M, Fraumeni JF Jr, Rabkin CS: Interleukin- 1 polymorphisms associated with increased risk of gastric cancer. Nature 2000; 404: 398-402. (Pubitemid 30164342)
36. El-Omar EM, Rabkin CS, Gammon MD, Vaughan TL, Risch HA, Schoenberg JB, Stanford JL, Mayne ST, Goedert J, Blot WJ, Fraumeni JF Jr, Chow WH: Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms. Gastroenterology 2003; 124: 1193-1201. (Pubitemid 36531795)
37. Xue H, Lin B, Ni P, Xu H, Huang G: Interleukin- 1B and interleukin-1 RN polymorphisms and gastric carcinoma risk: A metaanalysis. J Gastroenterol Hepatol 2010; 25: 1604-1617.
38. Peleteiro B, Lunet N, Carrilho C, Duraes C, Machado JC, La Vecchia C, Barros H: Association between cytokine gene polymorphisms and gastric precancerous lesions: Systematic review and meta-Analysis. Cancer Epidemiol Biomarkers Prev 2010; 19: 762-776.
39. Kupcinskas L, Wex T, Kupcinskas J, Leja M, Ivanauskas A, Jonaitis LV, Janciauskas D, Kiudelis G, Funka K, Sudraba A, Chiu HM, Lin JT, Malfertheiner P: Interleukin-1B and interleukin- 1 receptor antagonist gene polymorphisms are not associated with premalignant gastric conditions: A combined haplotype analysis. Eur J Gastroenterol Hepatol 2010; 22: 1189-1195.
40. Sugimoto M, Yamaoka Y, Furuta T: Influence of interleukin polymorphisms on development of gastric cancer and peptic ulcer. World J Gastroenterol 2010; 16: 1188-1200.
41. Togawa S, Joh T, Itoh M, Katsuda N, Ito H, Matsuo K, Tajima K, Hamajima N: Interleukin- 2 gene polymorphisms associated with increased risk of gastric atrophy from Helicobacter pylori infection. Helicobacter 2005; 10: 172-178. (Pubitemid 40769947)
42. John S, Turner D, Donn R, Sinnott P, Worthington J, Ollier WE, Hutchinson IV, Hajeer AH: Two novel biallelic polymorphisms in the IL-2 gene. Eur J Immunogenet 1998; 25: 419-420. (Pubitemid 29037579)
43. Yamaoka Y, Kodama T, Kita M, Imanishi J, Kashima K, Graham DY: Relation between clinical presentation, Helicobacter pylori density, interleukin 1beta and 8 production, and cagA status. Gut 1999; 45: 804-811.
44. Mout R, Willemze R, Landegent JE: Repeat polymorphisms in the interleukin-4 gene (IL4). Nucleic Acids Res 1991; 19: 3763.
45. Kato I, Canzian F, Franceschi S, Plummer M, van Doorn LJ, Lu Y, Gioia-Patricola L, Vivas J, Lopez G, Severson RK, Schwartz AG, Munoz N: Genetic polymorphisms in antiinflammatory cytokine signaling and the prevalence of gastric precancerous lesions in Venezuela. Cancer Causes Control 2006; 17: 1183-1191. (Pubitemid 44470408)
46. Wang J, Pan HF, Hu YT, Zhu Y, He Q: Polymorphism of IL-8 in 251 allele and gastric cancer susceptibility: A meta-Analysis. Dig Dis Sci 2010; 55: 1818-1823.
47. Zhou Y, Li N, Zhuang W, Liu GJ, Wu TX, Yao X, Du L, Wei ML, Wu XT: Interleukin-10 -1082 promoter polymorphism associated with gastric cancer among Asians. Eur J Cancer 2008; 44: 2648-2654.
48. Zhuang W, Wu XT, Zhou Y, Liu L, Liu GJ, Wu TX, Yao X, Du L, Wei ML: Interleukin10 -592 promoter polymorphism associated with gastric cancer among Asians: A meta-Analysis of epidemiologic studies. Dig Dis Sci 2010; 55: 1525-1532.
49. Chen KF, Li B, Wei YG, Peng CJ: Interleukin- 10 -819 promoter polymorphism associated with gastric cancer among Asians. J Int Med Res 2010; 38: 1-8.
50. Wang SS, Purdue MP, Cerhan JR, Zheng T, Menashe I, Armstrong BK, Lan Q, Hartge P, Kricker A, Zhang Y, Morton LM, Vajdic CM, Holford TR, Severson RK, Grulich A, Leaderer BP, Davis S, Cozen W, Yeager M, Chanock SJ, Chatterjee N, Rothman N: Common gene variants in the tumor necrosis factor (TNF) and TNF receptor superfamilies and NF-kB transcription factors and non-Hodgkin lymphoma risk. PLoS One 2009; 4:e5360.
51. Jang WH, Yang YI, Yea SS, Lee YJ, Chun JH, Kim HI, Kim MS, Paik KH: The -238 tumor necrosis factor-Alpha promoter polymorphism is associated with decreased susceptibility to cancers. Cancer Lett 2001; 166: 41-46. (Pubitemid 32274283)
52. Hohjoh H, Tokunaga K: Allele-specific binding of the ubiquitous transcription factor OCT-1 to the functional single nucleotide polymorphism (SNP) sites in the tumor necrosis factor-Alpha gene (TNFA) promoter. Genes Immun 2001; 2: 105-109. (Pubitemid 33674236)
53. Gorouhi F, Islami F, Bahrami H, Kamangar F: Tumour-necrosis factor-A polymorphisms and gastric cancer risk: A meta-Analysis. Br J Cancer 2008; 98: 1443-1451. (Pubitemid 351543569)
54. Zhou P, Lv GQ, Wang JZ, Li CW, Du LF, Zhang C, Li JP: The TNF-Alpha-238 polymorphism and cancer risk: A meta-Analysis. PLoS One 2011; 6:e22092.
55. Goto Y, Ando T, Yamamoto K, Tamakoshi A, El-Omar E, Goto H, Hamajima N: Association between serum pepsinogens and polymorphism of PTPN11 encoding SHP-2 among Helicobacter pylori seropositive Japanese. Int J Cancer 2006; 118: 203-208. (Pubitemid 41681600)
56. Chamaillard M, Hashimoto M, Horie Y, Masumoto J, Qiu S, Saab L, Ogura Y, Kawasaki A, Fukase K, Kusumoto S, Valvano MA, Foster SJ, Mak TW, Nunez G, Inohara N: An essential role for NOD1 in host recognition of bacterial peptidoglycan containing diaminopimelic acid. Nat Immunol 2003; 4: 702-707. (Pubitemid 36874448)
57. Kara B, Akkiz H, Doran F, Bayram S, Erken E, Gumurdullu Y, Sandikci M: The significance of E266K polymorphism in the NOD1 gene on Helicobacter pylori infection: An effective force on pathogenesis? Clin Exp Med 2010; 10: 107-112.
58. Hold GL, Rabkin CS, Chow WH, Smith MG, Gammon MD, Risch HA, Vaughan TL, Mc- Coll KE, Lissowska J, Zatonski W, Schoenberg JB, Blot WJ, Mowat NA, Fraumeni JF Jr, El-Omar EM: A functional polymorphism of Toll-like receptor 4 gene increases risk of gastric carcinoma and its precursors. Gastroenterology 2007; 132: 905-912. (Pubitemid 46440859)
59. Hishida A, Matsuo K, Goto Y, Mitsuda Y, Hiraki A, Naito M, Wakai K, Tajima K, Hamajima N: Toll-like receptor 4 +3725 G/C polymorphism, Helicobacter pylori seropositivity, and the risk of gastric atrophy and gastric cancer in Japanese. Helicobacter 2009; 14: 47-53.
60. Kupcinskas J, Wex T, Bornschein J, Selgrad M, Leja M, Juozaityte E, Kiudelis G, Jonaitis L, Malfertheiner P: Lack of association between gene polymorphisms of angiotensin converting enzyme, Nod-like receptor 1, Toll-like receptor 4, FAS/FASL and the presence of Helicobacter pylori -induced premalignant gastric lesions and gastric cancer in Caucasians. BMC Med Genet 2011; 12: 112.
61. Sun LP, Guo XL, Zhang Y, Chen W, Bai XL, Liu J, Yuan Y: Impact of pepsinogen C polymorphism on individual susceptibility to gastric cancer and its precancerous conditions in a Northeast Chinese population. J Cancer Res Clin Oncol 2009; 135: 1033-1039.
62. Blaser MJ: Polymorphic bacteria persisting in polymorphic hosts: Assessing Helicobacter pylori -related risks for gastric cancer. J Natl Cancer Inst 2002; 94: 1662-1663. (Pubitemid 35452506)
63. Chiurillo MA, Moran YH, Canas M, Valderrama EJ, Armanie E: Infection with specific Helicobacter pylori -cag pathogenicity island strains is associated with interleukin-1B gene polymorphisms in Venezuelan chronic gastritis patients. Dig Dis Sci 2011; 56: 449-456.
64. Fitzgerald RC, Hardwick R, Huntsman D, Carneiro F, Guilford P, Blair V, Chung DC, Norton J, Ragunath K, Van Krieken JH, Dwerryhouse S, Caldas C: Hereditary diffuse gastric cancer: Updated consensus guidelines for clinical management and directions for future research. J Med Genet 2010; 47: 436-444.
65. Ambros V: The functions of animal micro- RNAs. Nature 2004; 431: 350-355.
66. Meltzer PS: Cancer genomics: Small RNAs with big impacts. Nature 2005; 435: 745-746. (Pubitemid 40839710)
67. Chen JF, Mandel EM, Thomson JM, Wu Q, Callis TE, Hammond SM, Conlon FL, Wang DZ: The role of microRNA-1 and micro- RNA-133 in skeletal muscle proliferation and differentiation. Nat Genet 2006; 38: 228-233. (Pubitemid 43177239)
68. Paranjape T, Slack FJ, Weidhaas JB: Micro- RNAs: tools for cancer diagnostics. Gut 2009; 58: 1546-1554.
69. Zhou H, Guo JM, Lou YR, Zhang XJ, Zhong FD, Jiang Z, Cheng J, Xiao BX: Detection of circulating tumor cells in peripheral blood from patients with gastric cancer using microRNA as a marker. J Mol Med 2010; 88: 709-717.
70. Guo J, Miao Y, Xiao B, Huan R, Jiang Z, Meng D, Wang Y: Differential expression of microRNA species in human gastric cancer versus non-Tumorous tissues. J Gastroenterol Hepatol 2009; 24: 652-657.
71. Mostert B, Sieuwerts AM, Martens JW, Sleijfer S: Diagnostic applications of cellfree and circulating tumor cell-Associated miRNAs in cancer patients. Expert Rev Mol Diagn 2011; 11: 259-275.
72. Liu R, Zhang C, Hu Z, Li G, Wang C, Yang C, Huang D, Chen X, Zhang H, Zhuang R, Deng T, Liu H, Yin J, Wang S, Zen K, Ba Y, Zhang CY: A five-microRNA signature identified from genome-wide serum microRNA expression profiling serves as a fingerprint for gastric cancer diagnosis. Eur J Cancer 2011; 47: 784-791.
73. Ueda T, Volinia S, Okumura H, Shimizu M, Taccioli C, Rossi S, Alder H, Liu CG, Oue N, Yasui W, Yoshida K, Sasaki H, Nomura S, Seto Y, Kaminishi M, Calin GA, Croce CM: Relation between microRNA expression and progression and prognosis of gastric cancer: A microRNA expression analysis. Lancet Oncol 2010; 11: 136-146.
74. Okubo M, Tahara T, Shibata T, Yamashita H, Nakamura M, Yoshioka D, Yonemura J, Ishizuka T, Arisawa T, Hirata I: Association between common genetic variants in pre-microRNAs and gastric cancer risk in Japanese population. Helicobacter 2010; 15: 524-531.
75. Zeng Y, Sun QM, Liu NN, Dong GH, Chen J, Yang L, Wang B: Correlation between premiR- 146a C/G polymorphism and gastric cancer risk in Chinese population. World J Gastroenterol 2010; 16: 3578-3583.
76. Claerhout S, Lim JY, Choi W, Park YY, Kim K, Kim SB, Lee JS, Mills GB, Cho JY: Gene expression signature analysis identifies vorinostat as a candidate therapy for gastric cancer. PLoS One 2011; 6:e24662.
77. Kalnina Z, Silina K, Bruvere R, Gabruseva N, Stengrevics A, Barnikol-Watanabe S, Leja M, Line A: Molecular characterisation and expression analysis of SEREX-defined antigen NUCB2 in gastric epithelium, gastritis and gastric cancer. Eur J Histochem 2009; 53: 7-18.
78. Zilberman Y, Tisch U, Shuster G, Pisula W, Feng X, Mullen K, Haick H: Carbon nanotube/ hexa-peri-hexabenzocoronene bilayers for discrimination between nonpolar volatile organic compounds of cancer and humid atmospheres. Adv Mater 2010; 22: 4317-4320.
79. Record M, Subra C, Silvente-Poirot S, Poirot M: Exosomes as intercellular signalosomes and pharmacological effectors. Biochem Pharmacol 2011; 81: 1171-1182.
80. Yasui W, Oue N, Ito R, Kuraoka K, Nakayama H: Search for new biomarkers of gastric cancer through serial analysis of gene expression and its clinical implications. Cancer Sci 2004; 95: 385-392. (Pubitemid 38832680)